


## Levcromakalim

Cat. No.:	HY-14255		
CAS No.:	94535-50-9		
Molecular Formula:	C <sub>16</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>		
Molecular Weight:	286.33		
Target:	Potassium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (174.62 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.4925 mL	17.4624 mL	34.9247 mL
	5 mM	0.6985 mL	3.4925 mL	6.9849 mL
	10 mM	0.3492 mL	1.7462 mL	3.4925 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Levcromakalim ((-)-Cromakalim) is an ATP-sensitive K<sup>+</sup> channel (K<sub>ATP</sub>) activator.

#### IC<sub>50</sub> & Target

K<sup>+</sup> channel<sup>[1]</sup>

#### In Vitro

Levcromakalim ((-)-Cromakalim) inhibits spontaneous contractions completely in a glibenclamide-sensitive manner. LevCromakalim (5 μM) inhibits spontaneous contractions, which are recovered by glibenclamide. Levcromakalim (1, 5 and 10 μM) inhibits phasic contractions to 34±21.1%, 20.1±20.0% and 0% of the control (n=5, respectively; P<0.05). Glibenclamide reverses the inhibition of spontaneous isometric contractions caused by LevCromakalim (5 μM) to 84±1.5% of the control (n=5; P<0.05). Levcromakalim (20 and 100 μM) also inhibits oxytocin (OXT) (10 nM)-induced phasic contractions

to 34±21.4% and 14±12.6% of the control (n=6 and 4, respectively; P<0.05). Glibenclamide reverses the inhibition of spontaneous isometric contractions by LevCromakalim (100 μM) to 79±3.5% of the control (n=4; P<0.05). Tonic contraction by OXT is also suppressed by Cromakalim in a glibenclamide-sensitive manner<sup>[2]</sup>. The function of the K<sub>ATP</sub> channels is examined with the specific channel opener LevCromakalim (Cromakalim). LevCromakalim induces dose-dependent relaxation in both the young and old mesenteric artery (MAs); and there is no difference in relaxation with age. However, the relaxation is markedly reduced in response to the high-salt (HS) diet in the old MAs (P<0.05)<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Kinase Assay <sup>[3]</sup>

Levcromakalim (Cromakalim) is dissolved in 10% DMSO and Krebs solution<sup>[3]</sup>.

The endothelium-dependent relaxation is tested by performing concentration-response experiments with acetylcholine (ACh; 10 nM-10 μM). Typically, MAs are exposed to each dose of ACh for at least 6 minutes and maximal responses are determined. Function of the K<sub>ATP</sub> channels are examined with 10 μM of glibenclamide (a selective K<sub>ATP</sub> channel inhibitor) and LevCromakalim (Cromakalim) (10 nM to 100 μM), a K<sub>ATP</sub> channel opener. The addition of glibenclamide to the arterial bath 10 minutes prior to ACh does not alter passive maximum internal diameters of any MAs in our groups. The vessel diameter changes are presented as percentages (%) of dilation of the precontracted vessels, calculated<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Commun. 2022 May 13;13(1):2675.
- J Headache Pain. 2022 Sep 30;23(1):128.
- Cephalalgia. 2021 Aug 18;3331024211038884.
- Research Square Print. August 19th, 2022.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Matsumoto T, et al. Tunicamycin-Induced Alterations in the Vasorelaxant Response in Organ-Cultured Superior Mesenteric Arteries of Rats. Biol Pharm Bull. 2016;39(9):1475-81.

[2]. Hong SH, et al. Regulation of myometrial contraction by ATP-sensitive potassium (KATP) channel via activation of SUR2B and Kir 6.2 in mouse. J Vet Med Sci. 2016 Aug 1;78(7):1153-9.

[3]. Whidden MA, Altered potassium ATP channel signaling in mesenteric arteries of old high salt-fed rats. J Exerc Nutrition Biochem. 2016 Jun;20(2):58-64.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA